StablevaX™ is a disruptive platform technology that aims to produce fridge-free vaccines to eliminate the need for the global cold chain, reduce vaccine wastage and save lives through better immunisation
Stablepharma completes first close of Series A raise with £2 million following announcements of high-profile partnershipsStablepharma has achieved a scientific breakthrough, demonstrating that a fridge-free Tetanus diphtheria (Td) vaccine is possible
StablevaX™ - Fridge-Free Platform Technology
Our novel patented StablevaX™ technology can thermally stabilise and deliver a wide range of vaccines without the requirement for refrigeration. Stablepharma has developed a fridge-free vaccine solution that could eliminate the need for the cold chain and enable stockpiling anywhere in the world.
StablevaX™ is designed to dramatically enhance the performance of existing and new vaccines. Stablepharma stands to revolutionise the vaccine industry, by helping shield vaccines from temperature-related deterioration and wastage.
StablevaX™ has shown strong in-vitro and in-vivo data on stabilising range of vaccines including Tetadif (Td) and naked COVID mRNA. Stablepharma R&D team believe that the StablevaX™ technology could be applicable to over 60 vaccines.
Latest Press Coverage StablevaX™
Stablepharma Technology
StablevaX™ is a patented product that aims for enhanced thermostability, following WHO protocols
Zero Refrigeration
StablevaX™ technology aims to eliminate the need for refrigeration
Thermostable Vaccines
StablevaX™ technology is designed with the aim of administering to patients without any change to current practice
Our white paper
StablevaX™ - a complementary technology for COVID-19 vaccines
In light of the ongoing Covid-19 pandemic, the challenge of equitable and efficient vaccine delivery has never been starker. Stablepharma believes that StablevaX™ could be a crucial complementary technology to currently available Covid-19 vaccines, especially those using mRNA-based approaches.
